Biotech News
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
investor.inva.com2026-05-06 14:56 EST
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 13, 2025-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that two of the company’s infectious disease therapies, ZEVTERA ® (ceftobiprole medocaril sodium for injection) and XACDURO ® (sulbactam/durlobactam for